Veracyte (VCYT) Other Operating Expenses (2012 - 2026)

Veracyte has reported Other Operating Expenses for 15 years, with the latest figure at $28.7 million in Q2 2026.

• Other Operating Expenses for Q2 2026 came in at $28.7 million, down 23.28% year-over-year; the trailing twelve-month figure through Jun 2026 was $94.4 million (down 2.86% YoY), and the FY2025 annual result was $93.8 million, up 23.5% from the prior year.
• Other Operating Expenses improved to $28.7 million in Q2 2026, from $27.7 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $51.2 million in Q4 2023 and troughed at -$77.5 million in Q4 2022.
• A 5-year average of $23.8 million and a median of $25.3 million in 2024 frame the typical range for Other Operating Expenses.
• The widest annual swing landed in 2022, when Other Operating Expenses slumped 300.67%; it then soared 166.14% in 2023.
• A 5-year view of Other Operating Expenses shows it stood at -$77.5 million in 2022, then soared by 166.14% to $51.2 million in 2023, then slumped by 55.42% to $22.8 million in 2024, then slipped by 6.0% to $21.5 million in 2025, then surged by 33.59% to $28.7 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $28.7 million in Q2 2026, $27.7 million in Q1 2026, and $21.5 million in Q4 2025.